Diethylcarbamazine

證據等級: L5

預測適應症: 2 個

Diethylcarbamazine: From Lymphatic Filariasis to Syndromic Lymphedema

One-Sentence Summary

Diethylcarbamazine (DEC) is the WHO-endorsed first-line antiparasitic agent for lymphatic filariasis, effective against the filarial nematodes Wuchereria bancrofti and Brugia malayi, and is the cornerstone of the Global Programme to Eliminate Lymphatic Filariasis. The TxGNN model predicts it may be effective for Syndromic Lymphedema—the category of lymphedema arising in the context of a defined systemic condition, of which filarial infection is the archetypal cause. Currently, no registered clinical trials and 4 publications specifically support this endpoint, placing evidence at the L4 (Mechanism Inference) level.

Quick Overview

Item	Content
Original Indication	Lymphatic filariasis (antifilarial treatment)
Predicted New Indication	Syndromic Lymphedema
TxGNN Prediction Score	99.59%
Evidence Level	L4
Philippines Market Status	✗ Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Diethylcarbamazine (DEC) acts through multiple complementary mechanisms to eliminate filarial parasites: (1) it inhibits arachidonic acid metabolism, depriving microfilariae of motility; (2) it activates host antibody-dependent cell-mediated cytotoxicity (ADCC), directing immune effector cells to destroy parasite surfaces; and (3) it directly disrupts microfilaria surface membrane integrity. These actions target both larval microfilariae in the bloodstream and adult worms residing within lymphatic vessels.

Lymphatic filariasis is the single largest cause of secondary lymphedema worldwide, responsible for approximately 16 million cases of lymphedema and elephantiasis across 83 endemic countries. Adult filarial worms residing in the lymphatics provoke chronic inflammation, progressive vessel dilation, and fibrosis—the pathological cascade that ultimately results in irreversible limb swelling. “Syndromic lymphedema” encompasses lymphedema arising in the defined context of an underlying systemic disease, making filariasis a prototypical driver.

The mechanistic logic is therefore straightforward: by eradicating or suppressing the parasites, DEC halts the cycle of lymphatic injury before irreversible structural damage occurs. The prediction is biologically plausible and supported by decades of filarial biology research. The critical limitation, however, is that all current evidence uses microfilaremia clearance or infection prevalence as endpoints—not syndromic lymphedema progression or severity—making this mechanistic inference rather than direct clinical proof.

Clinical Trial Evidence

Currently no related clinical trials registered specifically for syndromic lymphedema.

Cross-indication note: Six clinical trials involving DEC for the rank-2 predicted indication Primary Lymphedema (TxGNN score 99.25%, evidence level L2) are available and are summarised in the Conclusion section below.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
1580599	1992	Review/Clinical Series	Annual Review of Medicine	Comprehensive review of tropical pulmonary eosinophilia (TPE) caused by immunologic hyperresponsiveness to W. bancrofti or B. malayi; DEC is the established treatment; documents pulmonary and lymphatic complications of filarial infection
9659744	1998	Review	Revista do Hospital das Clinicas	Differential diagnosis of filarial TPE versus similar syndromes; reviews pathophysiology, treatment, and new advances in understanding lymphatic filariasis complications
29549133	2018	Case Report	BMJ Case Reports	Parasitic chyluria (a chronic lymphatic filariasis complication) in a 7-year-old child; full remission achieved with DEC medical management, sustained at 1-year follow-up; highlights paediatric filarial lymphatic disease
24772754	2013	Case Report/Series	Journal of the Association of Physicians of India	Filariasis with chyluria and nephrotic-range proteinuria; successfully treated with DEC plus pelvic sclerotherapy; asymptomatic at 19-month follow-up; confirms DEC efficacy in filarial lymphatic complications

Philippines Market Information

Diethylcarbamazine is currently not registered with the Food and Drug Administration of the Philippines. No drug licenses, product authorisations, or market approvals are on record for any dosage form.

Safety Considerations

Please refer to the package insert for safety information.

No Philippines-specific warning, contraindication, or drug interaction data are available in this Evidence Pack. Clinicians should be aware that DEC can precipitate a Mazzotti reaction—an acute systemic inflammatory response caused by rapid killing of microfilariae—characterised by fever, pruritus, urticaria, and transient hypotension. This is a well-documented class effect requiring clinical monitoring. Full prescribing information should be obtained from WHO technical documents or the originating manufacturer prior to any clinical consideration.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence for DEC specifically targeting syndromic lymphedema as a clinical endpoint remains at the mechanistic inference level (L4), with no registered clinical trials and only indirect case-report and review literature. The prediction is biologically coherent, but no study has used lymphedema severity or progression as a primary outcome measure.

Important cross-indication finding: The rank-2 predicted indication, Primary Lymphedema (TxGNN score 99.25%), carries a substantially stronger evidence base:

Trial	Phase	Status	N	Relevance
NCT02899936	N/A	Completed	23,789	Grade A — Largest direct comparison of DEC+ALB vs IVM+DEC+ALB in LF elimination; microfilaremia clearance as primary endpoint
NCT03676140	Phase 3	Completed	20,000	Grade A — Phase 3 cluster RCT evaluating IDA triple-therapy safety for LF; highest-quality DEC-containing trial
NCT03268252	N/A	Completed	3,200	Grade B — MDA optimisation trial in Papua New Guinea monitoring DEC+ALB efficacy via infection prevalence
NCT02974049	N/A	Completed	189	Grade B — Alternative LF chemotherapy trial in Côte d’Ivoire; provides DEC positioning data in Africa
NCT03036059	Phase 4	Completed	1,462	Grade B — IVM+ALB frequency comparison in Ghana; DEC indirect comparator data
NCT07159373	Phase 3	Not yet recruiting	5,100	Grade C — Moxidectin vs IVM in combination with DEC+ALB; recruiting 2026 in Fiji

However, a critical conceptual mismatch must be resolved before treating rank-2 as actionable: the clinical trials and literature uniformly address filariasis-associated secondary lymphedema, while “Primary Lymphedema” in clinical nosology denotes genetic or congenital lymphatic developmental abnormalities (e.g., Milroy disease caused by FLT4 mutations, Meige syndrome). DEC has no plausible mechanism in genetic lymphatic dysplasia. TxGNN may have mapped both conditions through a shared “lymphedema” knowledge-graph node, producing a disease classification mismatch.

To proceed, the following is needed:

Clarify target disease definition: Confirm whether the intended clinical target is “filariasis-induced secondary lymphedema” rather than true primary (genetic) or syndromic lymphedema; this single clarification would unlock the L2 evidence base
Resolve Data Gap DG002 (MOA): Retrieve full mechanism-of-action data from DrugBank API for DB00711 to strengthen mechanistic justification
Resolve Data Gap DG001 (Safety): Obtain Philippines FDA or WHO package insert to characterise Mazzotti reaction risk, contraindications in renal/hepatic impairment, and special population warnings
Philippines epidemiological assessment: Confirm prevalence and geographic distribution of lymphatic filariasis in the Philippines to establish unmet clinical need and programme context
Endpoint realignment: If proceeding, redesign evidence synthesis around lymphedema clinical outcomes (limb circumference, lymphedema staging, quality of life) rather than microfilaremia-only surrogate endpoints
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.